Latest Breaking News On - தடுப்பூசி நிறுவனம் - Page 15 : comparemela.com

Bharat Biotech’s Covaxin has been given the regular emergency use authorisation in public interest, putting it on a par with the approval granted to Serum Institute’s Covishield’s, V K Paul, member-health, Niti Aayog told reporters on Thursday. Health Secretary Rajesh Bhushan added that the government has renegotiated the price of vaccines at a much lower level than before, without sharing any further details. “Earlier price was Rs 200 per dose and Rs 210 with taxes. After that, the re-negotiated price is significantly lower than this.” Paul added: “Covaxin is now allowed for restricted use in emergency usage in public interest. The vaccine has stood the test of time in terms of great safety. Covaxin is now in regular emergency use authorisation, the same as Covishield,” Paul told reporters.

Rajesh bhushanSerum institute covishieldExpert panelBharat biotechSerum instituteNiti aayogSecretary rajesh bhushanSubject expert panelSerum institutesCoromavirus vaccineVaccine companyPharma companyராஜேஷ் பூஷன்நிபுணர் குழுபாரத் பயோடெக்சீரம் நிறுவனம்